Trials / Suspended
SuspendedNCT05153395
Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation
Novel Treatment for Brain Insulin Resistance and Hypoperfusion
- Status
- Suspended
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Carbon dioxide breathing | Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure. |
| OTHER | Neurovascular Coupling | Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure. |
| DRUG | Human insulin | Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device. |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2021-12-10
- Last updated
- 2025-12-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05153395. Inclusion in this directory is not an endorsement.